West: Drada & Nagar Haveli, Daman & Diu, Goa, Gujarat, Maharashtra
South: Andhra Pradesh & Telangana, Karnataka, Kerala, Puducherry, Tamil Nadu
This technical document consists of epidemiological profiles (fact-sheets) for States and districts based on information available from multiple d...ata sources including the HIV Sentinel Surveillance (HSS) and the Integrated Biological and Behavioural Surveillance (IBBS). Given the need for focussed prevention efforts in low/high prevalence and vulnerable States/districts, the information presented will be useful for policy makers, program planners at national/State/ district level, researchers, and academicians in identification of areas for priority attention and also to derive meaningful conclusions for programme planning, implementation, monitoring and scale-up. This document will be a quick reference for the HIV/AIDS situation in a State/district, risk and safe behaviour of the high risk groups, their level of knowledge about STIs and HIV/AIDS, experience of violence, HIV testing and ART awareness and exposure to HIV/AIDS prevention.
more
DEMOGRAPHIC RESEARCH, VOLUME 36, ARTICLE 37, PAGES 1081-1108; PUBLISHED 5 APRIL 2017; http://www.demographic-research.org/Volumes/Vol36/37/; DOI: 10.4054/DemRes.2017.36.37
This 2011 update of Guidelines for the programmatic management of drug-resistant tuberculosis is intended as a tool for use by public health professionals working in response
to the Sixty-second World Health Assembly’s resolution on prevention and control of multidrug-resistant tuberculosis and e...xtensively drug-resistant tuberculosis.
more
The new WHO guidelines recommend that people living with HIV be started on antiretrovirals (ARVs) as soon as possible after being diagnosed. Currently, many people living with the virus globally must wait until their CD4 counts fall to 500 to start treatment. According to the WHO, the move to early ...treatment –or what some have dubbed the “test and treat” model –is backed by the latest research.
more
1.HIV infections – drug therapy. 2.Anti-HIV agents – adverse effects. 3.Anti-retroviral agents. 4.Benzoxazines – adverse effects. 5.Pregnancy. 6.Disease transmission, Vertical - prevention and control. 7.Treatment outcome. I.World Health Organization